Throughout the current 3 months, 8 experts have actually shared their insights on Incyte INCY, revealing a range of viewpoints covering from bullish to bearish.
The table listed below offers a succinct introduction of current scores by experts, providing insights into the altering beliefs over the previous 1 month and drawing contrasts with the preceding months for a holistic viewpoint.
| Bullish | Rather Bullish | Indifferent | Rather Bearish | Bearish | |
|---|---|---|---|---|---|
| Overall Scores | 0 | 0 | 8 | 0 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 0 | 0 | 1 | 0 | 0 |
| 2M Ago | 0 | 0 | 3 | 0 | 0 |
| 3M Ago | 0 | 0 | 3 | 0 | 0 |
Experts supply much deeper insights through their evaluations of 12-month rate targets, exposing a typical target of $69.62, a high price quote of $92.00, and a low price quote of $59.00. Observing a down pattern, the existing average is 0.54% lower than the previous typical rate target of $70.00.
Understanding Expert Scores: An Extensive Analysis
An extensive assessment of how economists view Incyte is stemmed from current expert actions. The following is an in-depth summary of crucial experts, their current examinations, and modifications to scores and rate targets.
| Expert | Expert Company | Action Taken | Score | Existing Rate Target | Previous Rate Target |
|---|---|---|---|---|---|
| Ashwani Verma | UBS | Maintains | Neutral | $ 61.00 | $ 61.00 |
| Srikripa Devarakonda | Truist Securities | Raises | Hold | $ 73.00 | $ 72.00 |
| Derek Archila | Wells Fargo | Raises | Equal-Weight | $ 59.00 | $ 58.00 |
| Brian Abrahams | RBC Capital | Raises | Sector Perform | $ 67.00 | $ 64.00 |
| Jessica Fye | JP Morgan | Reduces | Neutral | $ 68.00 | $ 70.00 |
| Vikram Purohit | Morgan Stanley | Reduces | Equal-Weight | $ 65.00 | $ 69.00 |
| Srikripa Devarakonda | Truist Securities | Reduces | Hold | $ 72.00 | $ 74.00 |
| Michael Schmidt | Guggenheim | Maintains | Neutral | $ 92.00 | $ 92.00 |
Secret Insights:
- Action Taken: In action to vibrant market conditions and business efficiency, experts upgrade their suggestions. Whether they ‘Maintain’, ‘Raise’, or ‘Lower’ their position, it symbolizes their response to current advancements connected to Incyte. This insight provides a picture of experts’ viewpoints on the existing state of the business.
- Score: Providing a detailed view, experts examine stocks qualitatively, covering from ‘Outperform’ to ‘Underperform’. These scores communicate expectations for the relative efficiency of Incyte compared to the more comprehensive market.
- Rate Targets: Experts assess the characteristics of rate targets, offering price quotes for the future worth of Incyte’s stock. This contrast exposes patterns in experts’ expectations with time.
For important insights into Incyte’s market efficiency, think about these expert examinations together with vital monetary indications. Stay knowledgeable and make sensible choices utilizing our Scores Table.
Stay up to date on Incyte expert scores.
Learn More About Incyte Better
Incyte concentrates on the discovery and advancement of small-molecule drugs. The company’s leading drug, Jakafi, deals with 2 kinds of unusual blood cancer and graft versus host illness and is partnered with Novartis. Incyte’s other marketed drugs consist of rheumatoid arthritis treatment Olumiant (certified to Lilly), and oncology drugs Iclusig (persistent myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (scattered big B-cell lymphoma). The company’s very first dermatology item, Opzelura, was authorized in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte’s pipeline consists of a broad range of oncology and dermatology programs.
Incyte: A Financial Introduction
Market Capitalization Analysis: Falling listed below market criteria, the business’s market capitalization shows a lowered size compared to peers. This positioning might be affected by elements such as development expectations or functional capability.
Profits Development: Incyte’s impressive efficiency in 3M appears. Since 31 March, 2025, the business attained a remarkable profits development rate of 19.53% This symbolizes a significant boost in the business’s top-line profits. When compared to others in the Healthcare sector, the business stood out with a development rate greater than the average amongst peers.
Net Margin: Incyte’s net margin stands out beyond market criteria, reaching 15.03% This symbolizes effective expense management and strong monetary health.
Return on Equity (ROE): Incyte’s monetary strength is shown in its extraordinary ROE, which surpasses market averages. With an impressive ROE of 4.45%, the business showcases effective usage of equity capital and strong monetary health.
Return on Possessions (ROA): The business’s ROA is a standout entertainer, going beyond market averages. With a remarkable ROA of 2.83%, the business showcases efficient usage of possessions.
Financial Obligation Management: The business keeps a well balanced financial obligation method with a debt-to-equity ratio listed below market standards, standing at 0.01
Expert Scores: Streamlined
Within the domain of banking and monetary systems, experts focus on reporting for particular stocks or specified sectors. Their work includes participating in business teleconference and conferences, investigating business monetary declarations, and interacting with experts to release “expert scores” for stocks. Experts usually examine and rank each stock when per quarter.
Beyond their basic examinations, some experts contribute forecasts for metrics like development price quotes, profits, and profits, providing financiers with extra assistance. Users of expert scores need to be conscious that this specialized suggestions is formed by human viewpoints and might undergo irregularity.
Breaking: Wall Street’s Next Huge Mover
Benzinga’s # 1 expert simply determined a stock poised for explosive development. This under-the-radar business might rise 200%+ as significant market shifts unfold. Click on this link for immediate information
This post was created by Benzinga’s automatic material engine and evaluated by an editor.